Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
AssigneeThe Cleveland Clinic Foundation
InventorsStanley L. Hazen, Zeneng Wang
Life of this patent
Estimating the term…
Abstract
A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof. The level of the systemic marker is compared with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent.
Claims15
A method for determining if a patient should be treated with a therapeutic agent targeted at treating cardiovascular disease, comprising:
- determining total protein bound or total free levels or both of one or more myeloperoxidase (MPO)-generated amino acids in a bodily sample of blood, serum, plasma, or urine from the patient,
- wherein the MPO-generated amino acids are selected from homocitrulline, methionine sulphoxide, nitrotyrosine, chlorotyrosine, and dityrosine,
- wherein at least one of the one or more MPO-generated amino acids is homocitrulline,
- comparing the levels of said one or more MPO-generated amino acids in the patient's bodily sample with a predetermined value, and
- determining that the patient should be treated with the therapeutic agent targeted at treating cardiovascular disease if the levels of said one or more MPO-generated amino acid in the patient's bodily sample is higher than the predetermined value.
A method for determining if a patient should be treated with a therapeutic agent targeted at treating cardiovascular disease, comprising:
- determining a level of total-protein bound or total free homocitrulline or both in a bodily sample of blood, serum, plasma, or urine from the patient,
- comparing the level of homocitrulline in the patient's bodily sample with a predetermined value, and
- determining that the patient should be treated with the therapeutic agent targeted at treating cardiovascular disease if the level of homocitrulline in the patient's bodily sample is higher than the predetermined value.
Dependencies are inferred from the claim text.